1. FDA. Uloric Highlights Of Prescribing Information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021856s013lbl.pdf
2. Bruce SP. Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother. 2006;40(12):2187–94.
5. Gliozzi M, Malara N, Muscoli S, Mollace V. The treatment of hyperuricemia. Int J Cardiol, 2016. 213:23–7. http://dx.doi.org/10.1016/j.ijcard.2015.08.087
7. National Center for Biotechnology Information. PubChem Compound Summary for CID 134018, Febuxostat. https://pubchem.ncbi.nlm.nih.gov/compound/Febuxostat. Accessed Oct. 22, 2021.
8. Pandey A, Chaturvedi M, Prakash H, Meena D. Febuxostat - A new treatment for hyperuricaemia in gout - A review article. Natl J Physiol Pharm Pharmacol. 2012;2(1):23–8.